Overview

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising IDegLira, metformin, and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.
Phase:
Phase 3
Details
Lead Sponsor:
Population Health Research Institute
Collaborator:
Novo Nordisk A/S
Treatments:
Insulin
Insulin, Globin Zinc
Insulin, Long-Acting
Liraglutide
Metformin
Xultophy